drugset
drugset / Trial / NCT00470197

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

NCT00470197 ↗

Phase 1 Completed 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy, such as flavopiridol, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving a new schedule of more than one drug (combination chemotherapy) may kill more cancer cells. This phase I trial is studying the side effects, best dose, and best schedule for flavopiridol when given together with cytarabine and mitoxantrone in treating patients with relapsed or refractory acute leukemia.

Timeline

Start
2007-04
Primary completion
2011-01
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject alvocidib Small molecule 50 mg/m2 Intravenous
Subject alvocidib Small molecule 90 mg/m2 Intravenous
Subject alvocidib Small molecule 100 mg/m2 Intravenous
Background Cytarabine Small molecule — Intravenous
Background Mitoxantrone Small molecule — Intravenous

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 adult acute lymphoblastic leukemia adult acute monocytic leukemia